Home
#Global Trends
#Local Dynamics
#M&A
#Regulations
#Knowledge

Category: Uncategorized

Verana Health acquires COTA Healthcare to lead RWD analytics market

14/01/2026 Published by vivi

Merger & Acquisition Update Verana Health, a real-world data (RWD) analytics firm, has announced the acquisition of oncology specialist COTA... Read more

Tags: #M&A

Axol Bioscience secures $2.8M for U.S. expansion and R&D

14/01/2026 Published by vivi

Investment Update U.K.-based Axol Bioscience, a specialist in induced pluripotent stem cell (iPSC) technologies, has secured $2.8 million (£2.1 million)... Read more

Category: Uncategorized

Tags: #Global Trends

Gilead HIV pipeline dosing optionality offers strategic competitive advantage

14/01/2026 Published by vivi

Strategic Spotlight At the 44th Annual J.P. Morgan Healthcare Conference, CEO Daniel O’Day outlined Gilead’s roadmap to sustain its dominance... Read more

Category: Uncategorized

Tags: #Global Trends

Sarepta seeks to restore gene therapy confidence after a turbulent year

14/01/2026 Published by vivi

Medical Spotlight At the 2026 J.P. Morgan Healthcare Conference, Sarepta Therapeutics CEO Douglas Ingram offered an optimistic outlook for the... Read more

Category: Uncategorized

Tags: #Global Trends

MSD homes in on derisking strategy amid Keytruda patent cliff

14/01/2026 Published by vivi

Strategic Insight At the 2026 J.P. Morgan Healthcare Conference, CEO Robert Davis outlined MSD’s roadmap to safeguard its financial future... Read more

Category: Uncategorized

Tags: #Global Trends

Vertex aims for five launches in five years across diverse disease areas

14/01/2026 Published by vivi

Growth Strategy At the 2026 J.P. Morgan Healthcare Conference, Vertex Pharmaceuticals CEO Reshma Kewalramani reaffirmed the company’s "five-in-five" goal: launching... Read more

Category: Uncategorized

Tags: #Global Trends

GSK leverages AI partnerships and late-stage acquisitions to offset patent cliffs

14/01/2026 Published by vivi

R&D Strategic Focus At the 44th Annual J.P. Morgan Healthcare Conference, GSK’s Chief Scientific Officer Tony Wood detailed the company’s... Read more

Category: Uncategorized

Tags: #Global Trends

Moderna aims for 2028 cash breakeven via seasonal respiratory vaccine franchise

14/01/2026 Published by vivi

Strategic Analysis At the 44th Annual J.P. Morgan Healthcare Conference, CEO Stéphane Bancel outlined Moderna’s comprehensive restructuring roadmap. Following the... Read more

Category: Uncategorized

Tags: #Global Trends